Kyoto University Innovation Capital Corporation (hereinafter referred to as "Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) has been selected as a certified venture capital (VC) in the "Drug Discovery Venture Ecosystem Enhancement Project" conducted by the Japan Agency for Medical Research and Development (AMED) The project will be implemented by the Japan Agency for Medical Research and Development (AMED).

Under this project, AMED and accredited VCs will collaborate to support drug discovery ventures that develop vaccines and therapeutics for infectious diseases, or that develop innovative technologies that have the potential to be converted to the development of vaccines and therapeutics for infectious diseases in the future. The AMED will be soliciting applications for the drug discovery ventures to be supported. Kyoto iCAP has invested the largest portion of its funds in the life science field to date, and with this approval, will further strengthen its support for this area.

• Adoption of Venture Capital in the "Drug Discovery Venture Ecosystem Enhancement Project (Accreditation of Venture Capital)
• Public Offering of "Drug Discovery Venture Ecosystem Enhancement Project (Public Offering of Drug Discovery Ventures)" (Japanese Only)